Chief Scientific Officer Stephen Betz sold 3,000 shares of Crinetics Pharmaceuticals Inc (CRNX, Financial) on August 12, 2024, according to a recent SEC Filing. Following this transaction, the insider now owns 72,611 shares of the company.
Crinetics Pharmaceuticals Inc is a biopharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors.
Over the past year, Stephen Betz has sold a total of 36,000 shares and has not purchased any shares. This recent transaction continues a trend observed over the past year, where there have been 35 insider sells and no insider buys at Crinetics Pharmaceuticals Inc.
Shares of Crinetics Pharmaceuticals Inc were trading at $47.68 on the day of the transaction. The company has a market cap of approximately $4.12 billion.
For more detailed valuation metrics, such as the GF Value, price-earnings ratio, price-sales ratio, price-book ratio, and price-to-free cash flow, investors can visit the respective links.
This insider sale may be of interest to investors tracking ownership changes and evaluating the stock's current valuation metrics.
This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein.
